Although anecdotal responses have been observed in women with ER- and PgR-negative tumours, in current clinical practice, only postmenopausal women with ER-positive and/or PgR-positive tumours are selected for treatment with AIs (9,16). This evidence concerns the gene PGR and neoplasm.